Infliximab exerts a dose-dependent effect on retinal safety in the albino rabbit

Doc Ophthalmol. 2017 Dec;135(3):175-185. doi: 10.1007/s10633-017-9606-x. Epub 2017 Aug 19.

Abstract

Purpose: To assess the retinal toxicity of an intravitreal injection of infliximab, a monoclonal antibody to tumor necrosis factor α, in a rabbit model.

Materials and methods: Two groups of adult albino rabbits (n = 5) received intravitreal injections of infliximab (0.1 ml) in the study eye and balanced salt solution (BSS, 0.1 ml) in the control eye at baseline. Group 1 was administered with 1.5 mg/0.1 ml, and group 2 was injected with 7.5 mg/0.1 ml of infliximab solution. Electroretinography (ERG) was performed at baseline and at 1, 7, 30, and 45 days after the injection. Visual evoked potentials (VEPs) were recorded at 7 and 45 days after the injection. After the last electrophysiological assessment, the rabbits were euthanized and retinal histopathology and immunhistochemistry for glial fibrillary acidic protein (GFAP) were performed.

Results: ERG responses demonstrated no significant deficit in retinal function in eyes injected with infliximab. Mean dark-adapted a-wave and b-wave maximal amplitude and semi-saturation constant values at baseline and throughout the 45 days of follow-up after the injection indicated no remarkable difference in outer retinal function between the control and experimental eyes. VEP responses were similar at each time point (7 and 45 days). No difference was seen in retinal histopathology and immunocytochemistry sections in eyes receiving the 1.5 mg/0.1 ml dose compared to the control eyes. However, increased GFAP labeling in retinal Müller cells was detected in rabbit eyes treated with the 7.5 mg/0.1 ml dose.

Conclusions: Intravitreal injection of 1.5 mg/0.1 ml infliximab dose has no toxic effect on the integrity (functional or structural) of the retina in rabbits. A higher dose of 7.5 mg/0.1 ml may be slightly toxic as suggested by positive Müller cell GFAP expression. Additional studies of retinal toxicity at higher doses and after multiple injections are needed to establish the retinal safety of intravitreal infliximab therapy in humans.

Keywords: Angiogenesis; Anti-tumor necrosis factor alpha; Infliximab; Rabbit; Retina; Toxicity.

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / toxicity*
  • Animals
  • Antibodies, Monoclonal
  • Electroretinography / drug effects
  • Ependymoglial Cells / metabolism
  • Evoked Potentials, Visual / drug effects
  • Eye Diseases / physiopathology
  • Glial Fibrillary Acidic Protein / metabolism
  • Infliximab / administration & dosage
  • Infliximab / toxicity*
  • Intravitreal Injections
  • Rabbits
  • Retina / drug effects*
  • Retina / metabolism
  • Retina / pathology
  • Tumor Necrosis Factor-alpha
  • Vitreous Body / metabolism

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Glial Fibrillary Acidic Protein
  • Tumor Necrosis Factor-alpha
  • Infliximab